Quest Laboratories Ltd
Incorporated in 1998, Quest Laboratories Ltd is a pharmaceutical manufacturer specializing in diverse therapeutic segments[1]
- Market Cap ₹ 152 Cr.
- Current Price ₹ 93.0
- High / Low ₹ 153 / 84.0
- Stock P/E 10.1
- Book Value ₹ 59.1
- Dividend Yield 0.00 %
- ROCE 18.4 %
- ROE 16.8 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 86.8% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 23.2%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Working capital days have increased from 129 days to 258 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of Nifty SME Emerge
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| 30 | 59 | 62 | 83 | 104 | 112 | |
| 29 | 53 | 54 | 67 | 88 | 94 | |
| Operating Profit | 1 | 6 | 8 | 16 | 16 | 18 |
| OPM % | 5% | 11% | 13% | 19% | 15% | 16% |
| 0 | 0 | 0 | 0 | 4 | 3 | |
| Interest | 0 | 0 | 1 | 1 | 1 | 2 |
| Depreciation | 0 | 0 | 1 | 1 | 1 | 1 |
| Profit before tax | 1 | 6 | 7 | 14 | 19 | 18 |
| Tax % | 18% | 29% | 28% | 30% | 27% | 17% |
| 1 | 4 | 5 | 10 | 14 | 15 | |
| EPS in Rs | 8.45 | 8.28 | 9.17 | |||
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 30% |
| 3 Years: | 22% |
| TTM: | 8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 87% |
| 3 Years: | 44% |
| TTM: | 11% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -16% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 26% |
| 3 Years: | 23% |
| Last Year: | 17% |
Balance Sheet
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 12 | 16 | 16 |
| Reserves | 5 | 9 | 14 | 17 | 65 | 80 |
| 3 | 3 | 4 | 5 | 30 | 8 | |
| 9 | 22 | 28 | 27 | 10 | 6 | |
| Total Liabilities | 18 | 35 | 47 | 61 | 122 | 111 |
| 6 | 7 | 10 | 10 | 12 | 15 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 1 |
| Investments | 0 | 0 | 0 | 7 | 52 | 16 |
| 12 | 27 | 37 | 44 | 58 | 79 | |
| Total Assets | 18 | 35 | 47 | 61 | 122 | 111 |
Cash Flows
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| 1 | 3 | 4 | 3 | -23 | -11 | |
| -1 | -2 | -4 | -5 | -44 | 35 | |
| 0 | -0 | 0 | 2 | 67 | -24 | |
| Net Cash Flow | -0 | 1 | 0 | 0 | -0 | -0 |
| Free Cash Flow | -0 | 2 | 1 | 2 | -27 | -16 |
| CFO/OP | 103% | 57% | 72% | 46% | -120% | -34% |
Ratios
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 110 | 135 | 118 | 108 | 105 | 118 |
| Inventory Days | 12 | 9 | 97 | 113 | 99 | 163 |
| Days Payable | 119 | 140 | 215 | 144 | 26 | 24 |
| Cash Conversion Cycle | 3 | 4 | 1 | 77 | 178 | 258 |
| Working Capital Days | 9 | 14 | 27 | 58 | 72 | 258 |
| ROCE % | 55% | 47% | 57% | 27% | 18% |
Insights
In beta| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Tablets Revenue INR Crore |
|
||||
| Liquid Syrup Capacity Utilization % |
|||||
| Ointment Capacity Utilization % |
|||||
| ORS Powder Capacity Utilization % |
|||||
| Tablets Capacity Utilization % |
|||||
| Government Institution Revenue Share % |
|||||
| Tablets Production Volume Million units |
|||||
| Total Licensed Formulations count |
|||||
Extracted by Screener AI
Documents
Announcements
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
13 July 2026 - Submitted Regulation 74(5) certificate for quarter ended June 30, 2026; no dematerialization requests received.
-
Trading Window
7 July 2026 - Trading window re-opened from July 7, 2026 after quarterly results disclosure change.
-
Updates
7 July 2026 - Quest Laboratories reopens trading window from July 7, 2026 after reverting to half-yearly results disclosure.
-
Updates
1 July 2026 - Quest Laboratories will report financial results half-yearly from FY2026-27, with September 30, 2026 results next.
-
Trading Window
26 June 2026 - Trading window closes from July 1, 2026 until 48 hours after Q1 FY2026 results.
Business Overview:[1][2]
a) QLL specializes in manufacturing a wide range of pharmaceutical formulations, including antibiotics, antimalarials, anti-inflammatories, respiratory medications,
diabetes treatments, and more.
b) Company also produces a wide range of ethical, generic, and over-the-counter (OTC) drugs in various forms, including tablets, liquids, oral powders, ORS, ointments, and external liquids.
c) Quest offers facilities for institutional supplies, domestic ethical products, PCD, Contract manufacturing, and export, with
a focus on a wide range of specialized formulations and molecules
d) The company has 800+ Licensed Formulations, 272+ Active Products, 25cr.+Order Book from Myanmar